tbuckley/cabot-search huggingface dataset:
Exploratory study of histopathological and biomolecular characteristics of breast cancer in two different populations: African (Tanzania) and Caucasian (Italy).
Authors: Patrizia Serra, Sara Bravaccini, Nestory Andrew Masalu, Maurizio Puccetti, Claudia Rengucci, Maria Maddalena Tumedei, Luigi Serra, Wainer Zoli, Dino Amadori
Journal: Journal of Clinical Oncology (2012)

10601 Background: There is little information available on the clinical and molecular epidemiology of breast cancer in Sub-Saharan African women. In Tanzania, breast cancer mortality is the second cause of death after cancer of the uterine cervix, with the majority of tumors diagnosed at a very advanced stage. We aimed to compare the distribution of histopathological and biomolecular characteristics (ER, PgR, Ki67, HER2, grading) of breast cancer in African (Tanzania) and Caucasian (Italy) patients. Methods: 142 women with invasive breast cancer, 71 from Tanzania and 71 from Italy, were considered. Histopathological classification and biomolecular determinations were performed at the Biosciences Laboratory of the Cancer Institute of Romagna (I.R.S.T., Meldola, Italy) as part of a joint Cancer Control Project between I.R.S.T and the Bugando Medical Center in Mwanza, Tanzania. All cases were evaluable for histopatological characterization, while biomolecular determination was possible in only 61 of the African patients. Hormone receptor status and Ki67 were determined by IHC; HER2 was evaluated by IHC for the African population and by FISH for the Italian one. Results: Whilst histopathological patterns were similar in the two populations, some biomolecular characteristics differed substantially. Of note, 64% of African breast cancer patients had ER negative tumors compared to only 17% of the Caucasian population. Important differences were observed in high Ki67 (&gt;15%) values: 76% in Tanzanian women vs 58% in Italian breast cancer cases. HER2 positivity rates also differed in the two populations (25% in Tanzanian and 17% in Italian patients), as did the incidence of triple negative disease (13% and 7% in African and Caucasian populations, respectively). Conclusions: This preliminary study shows that breast cancer in African (Tanzanian) women is characterized by a high frequency of HER2 positive, ER negative, highly proliferating tumors. These biological patterns, together with very advanced stage at diagnosis, could be considered the main prognostic factors related to the high mortality rates for breast cancer in this African population.
TEMPORAL TREND IN ATRIAL FIBRILLATION AND ATRIAL FLUTTER ASSOCIATED MORTALITY IN THE UNITED STATES (1999-2017)
Authors: Haider Al Taii, Ramez Morcos, Luis Mora, Ben Ravaee, Priya Bansal, Mark Freher, Houman Khalili, Eric Lieberman, Brijeshwar Maini, Yoel Vivas
Journal: Journal of the American College of Cardiology (2020)
Clinical significance of the EML4-ALK fusion gene and association with EGFR and KRASgene mutation in 208 Chinese patients with non-small cell lung cancer.
Authors: JUN Chen, Hongyu Liu, Tong Yang, Sen Wei, Qinghua Zhou
Journal: Journal of Clinical Oncology (2012)

e17514 Background: EML4-ALK fusion gene is a potentially relevant oncogenic event in lung cancer, which represents a new subgroup of non-small cell lung cancer (NSCLC) patients who respond positively to ALK inhibitors. The characteristics of EML4-ALK fusion gene in Chinese Patients with NSCLC are poorly understood. In this study, we aimed to analyze the prevalence of EML4-ALK fusion gene and their correlation to epidermal growth factor receptor (EGFR) status, KRAS mutation, and clinico-pathological data in Chinese patients with NSCLC. Methods: Genes were detected by nested RT-PCR and confirmed by sequencing. Results: 208 cases of NSCLC were evaluated. There were 24.5% (51/208 cases of mutations in EGFR at exons 18-21, and EGFR mutations occur predominantly (92%) in exons 19 and 21. In concordance with previous reports, these mutations are identified at high frequencies in females (47.5%, 29/61 vs 15.0%, 22/147 in males; P = 0.000); never-smokers (42.3%, 33/78 vs 13.9%, 18/130 in smokers; P = 0.000), and adenocarcinoma patients (44.2%, 42/95 vs 8.0%, 9/113 in non-adenocarcinoma patients; P = 0.000). There were only 6 cases (6/208, 2.88%) of KRAS mutations in our study group. We identified 7 patients who harbored the EML4-ALK fusion gene (3.37%, 7/208) which all confirmed by DNA sequencing. Of these 7 patients, 2 cases displayed the EML4-ALK variant 1 (28.6%), 1 case exhibited variant 2 (14.3%) and 4 cases carried variant 3 (57.1%). All of the positive cases corresponded to female patients (11.5%, 7/61). Six of the positive cases were non-smokers (7.69%, 6/78). The incidence of EML4-ALK translocation in female non-smoking adenocarcinoma patients is as high as 15.2% (5/33). No EGFR/KRAS mutations were detected among EML4-ALK positive patients. The meta-analysis demonstrated that EML4-ALK translocation was 4.71% (125/2652) in unselected patients with NSCLC, and was also predominant in female patients with adenocarcinoma. Conclusions: EML4-ALK translocations are infrequent in the entire NSCLC patient population, but are frequent in the NSCLC patient subgroup of female, nonsmokers, and adenocarcinoma patients.
Effect of metastasis surgery on overall survival in patients (pts) with advanced soft tissue sarcoma (ASTS): A subanalysis of the PALSAR trials.
Authors: Nuria Kotecki, Binh Bui Nguyen, Jean-Yves Blay, Simone Mathoulin-Pelissier, Christine Chevreau, Juliette Thariat, Didier Cupissol, Jacques-Olivier Bay, Jean-Michel Coindre, Jean-Pierre Lotz, Marta Jimenez, Veronique Brouste, Cecile Guillemet, Antoine Italiano, Nicolas Penel
Journal: Journal of Clinical Oncology (2012)

10035 Background: The role of surgery in pts with ASTS remains controversial. We have conducted an exploratory retrospective analysis of the role of metastasis surgery in ASTS pts receiving 1st-line chemotherapy (CT). Methods: The database includes all pts enrolled in PALSAR-1 and PALSAR-2 trials [Fayette 2009; Bui-Nguyen 2011], treated with dose-intensified MAID or high-dose CT with peripheral blood stem cells support as 1st-line treatment of ASTS. In our analysis, the primary endpoint is overall survival (OS). Log-ranks are used for univariate analysis and Cox model for multivariate analysis. Impact of treatments had been evaluated after adjustment to confounders (Cox Model). Confounders were defined as parameters with significantly different distribution in pts who underwent metastasis surgery and those who did not (p&lt;0.05) and significantly associated with OS (p&lt;0.05). Results: The database consists of 410 pts (160 in PALSAR-1 and 248 in PALSAR-2) with a median age of 43. Among them, 77 patients (18%) underwent metastasis surgery. At the end of the treatment, 61 pts experienced complete response (CR), 45 with CT alone and 16 with metastasis surgery and CT. The median follow-up was 29 months. The median OS was 35.7 months (29.9-41.5). The following parameters are associated with longer OS in univariate analysis: primary location (p=0.0001), performance status (p=0.010) and absence of liver metastasis (p=0.001). We identified 4 factors associated with metastasis surgery (n=76): limb/trunk primaries, young age, absence of liver metastasis and absence of progression of the target lesions after 4 cycles. The sole identified confounder was primary location. In multivariate analysis the 2 categories of patients experiencing significant longer OS are those with CR without surgery (HR=2.2, [1.7-5.8], p=0.0001) and those with CR following metastasis surgery (HR=3.8, [2.3-6.2], p=0.0001). Conclusions: Among the pts with ASTS receiving poly-CT as 1st-line treatment, the OS of pts experiencing CR with or without metastasis surgery appears similar. Metastatis surgery without CR does not offer significant OS advantage.
PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF MITRAL REGURGITATION IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY
Authors: Krishan Sivaraj, Sameer Arora, Patricia Chang, Thelsa T. Weickert, Arman Qamar, Muthiah Vaduganathan, Matthew Aaron Cavender, Wayne Rosamond, John Vavalle
Journal: Journal of the American College of Cardiology (2020)
Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide
Authors: Janice Hopkins Tanne, Erika Hayasaki, Mark Zastrow, Priyanka Pulla, Paul Smith, Acer Garcia Rada
Journal: BMJ (2020)

Cases in Japan have slowed in the weeks since the Diamond Princess cruise ship-responsible for nearly 700 cases-was cleared, and the government enacted emergency measures including the shutdown of all schools for the month of March and a public lockdown in the northern prefecture of Hokkaido.
Painful Cutaneous Plaques on the Lower Legs in a Middle-aged Woman
Authors: Yujie Wen, Lin Nong, Yang Wang
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A phase Ib proof-of-concept study of LBH589 (LBH) and everolimus (EVE) in advanced solid tumors enriched for Epstein-Barr virus (EBV)-related cancers.
Authors: Daniel Shao-Weng Tan, Quan Sing Ng, Dawn Qingqing Chong, Guek Eng Lee, Thuan Tong Tan, Noan Minh Chau, Mei-Kim Ang, Liz Zhong, Balram Chowbay, John Connolly, Eng-Huat Tan, Wan-Teck Lim
Journal: Journal of Clinical Oncology (2012)

3098 Background: Histone deacetylase and mTOR inhibition circumvent critical EBV-oncogenic pathways with preclinical studies demonstrating lytic induction in EBV infected cells, as well as immunomodulatory and antiangiogenic effects. Methods: Patients (Pt) with advanced solid tumors enriched for EBV–related cancers were enrolled to determine safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics and preliminary antitumor activity. LBH was instituted 7-days prior to combination treatment. NPC pt received antiviral prophylaxis of either acyclovir (Ac) or valaciclovir (Vc). Serum EBV DNA levels (EBNA-1) were measured weekly and plasma cytokines profiled using a 31-plex Luminex panel. Results: 15 pt have been treated (M:F 13:2, median age 50, R: 38-63) 10 NPC, 5 non-NPC (colon, RCC, breast, gastric, sarcoma) at 3 dose levels – LBH (3x/wk)-EVE (daily):10-2.5, 10-5, 15-5. Two dose limiting toxicities of G4 (grade) thrombocytopenia were observed at LBH15-RAD5. Significant adverse events (AE) (G≥3) were dysphagia (1) and thrombocytopenia (3). Common AEs (G1/2) included fatigue (80%), anorexia (60%), mucositis (53%), xerostomia (26%), dysphagia (26%). Two minor responses were seen (1 NPC, 1 breast) and 2 pt (1 NPC, 1 RCC) had prolonged stable disease (&gt;16 weeks). Modulation of EBV DNA titres was seen only in NPC pt, with median fold-change from baseline of 10.9 (0.05-174). Pt on Ac prophylaxis (n=5) had significant increases in DNA titres (9-174 fold), while those on Vc (n=4) were less pronounced (0.05-11 fold, p&lt;0.03), with one pt (with minor response) having persistent decline in EBV titres. In a limited pt subset (n=9, 30 timepoints), plasma cytokine profiles were consistent with a T-cell response, specifically, elevated levels of FLT3L, IFN-gamma, IL-13 and IL-17. PK and PBMC target modulation studies are being analysed. Conclusions: LBH-EVE results in induction of EBV DNA titres with an associated host T cell response. MTD is LBH10-EVE5 in Asian pt, majority of whom had NPC. A pre-planned expansion cohort that incorporates multi-parametric functional imaging exploring two schedules of LBH in combination with EVE5 is ongoing.
Prediction of skip mediastinal lymph node metastasis in surgical patients with clinical N0 non-small-cell lung cancer.
Authors: Rie Nakahara, Haruko Suzuki, Haruhisa Matsuguma, Seiji Igarashi
Journal: Journal of Clinical Oncology (2013)

e18554 Background: It has been reported that the prognosis of surgical non-small-cell lung cancer (NSCLC) patients with skip-N2 metastasis (without hilar lymph node metastasis) is generally more favorable than that of those with pathological N2 disease. Therefore, when a surgeon determines whether to perform mediastinal lymph node dissection, it is important to accurately predict skip-N2 metastasis in surgical patients without hilar lymph node metastasis. Methods: Of the patients who had undergone complete resection for NSCLC in our hospital between October 1986 and December 2010, 741 with cN0 NSCLC who had undergone mediastinal lymph node dissection were analyzed. The relationship between the lymph node metastasis status and clinicopathological parameters (age, gender, and serum CEA level, histological type, primary tumor location, tumor diameter, pleural invasion(pl), lymphatic invasion(ly), vascular invasion(v)) was analyzed, and factors that predict differences between pN0 and skip-N2 patients were identified. Results: Of the 741 patients, 609 had pN0 disease, 62 pN1 disease, and 70 pN2 disease. Of the pN2 patients, 23 had skip metastases to the mediastinal nodes alone. No significant difference was observed in the gender, age, or histological type between the N0 and skip N2 groups. However, the serum CEA level, tumor diameter, and pl(+) rate were significantly higher (p=0.0028), larger (mean, 3.7 cm, p=0.012), and higher (p=0.0064), respectively, in the skip-N2 group. Also, the ly(+) and v(+) rates were significantly higher in the skip-N2 group. Skip-N2 appeared more frequently with primary tumors in the lower lobes than with those in the upper lobes. Conclusions: Even if no hilar lymph node metastasis is found during surgery in patients with a high serum CEA level, large tumor diameter or lower lobe location, they may have skip-N2 lymph node metastasis. Although the p factor status becomes clear after surgery, patients with pleural indentation so marked as to raise the suspicion of pl(+) have a high probability of skip-N2 metastasis. Mediastinal lymph node dissection is preferable in these patients.
PROGNOSTIC IMPACT OF MILD PARAVALVULAR LEAK WITH NO PRE PROCEDURAL AORTIC REGURGITATION FOLLOWING TAVR
Authors: Yoshio Maeno, Masaki Miyasaka, Takahiro Nomura, Nobuhiko Ogata, Naoki Masuda, Sung-Han Yoon, Yoshio Kazuno, Nobuyuki Takahashi, Yigal Abramowitz, Takaaki Isshiki, Raj Makkar
Journal: Journal of the American College of Cardiology (2020)
REAL-WORLD THREE-YEAR OUTCOME IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE ERA OF TREATMENT WITH DIRECT ORAL ANTI-COAGULANTS: THE ASSAF-K REGISTRY
Authors: Yutaka Hatori, Hiroyuki Sakai, Tomoyuki Kunishima, Keiichi Chin, Nobuo Hatori, Naoki Sato
Journal: Journal of the American College of Cardiology (2020)
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
Authors: Kara L Davis, Elizabeth Fox, Melinda S Merchant, Joel M Reid, Rachel A Kudgus, Xiaowei Liu, Charles G Minard, Stephan Voss, Stacey L Berg, Brenda J Weigel, Crystal L Mackall
Journal: The Lancet Oncology (2020)
The case for assessing the full value of new tuberculosis vaccines
Authors: Nebiat Gebreselassie, Raymond Hutubessy, Johan Vekemans, Saskia den Boon, Tereza Kasaeva, Matteo Zignol
Journal: European Respiratory Journal (2020)

Tuberculosis (TB) ranks as the leading cause of death among infectious diseases in human history, claiming over a billion lives in the past two centuries alone [1, 2]. Although a number of important advances have been made to control TB in the past decade, an estimated 10 million people fell ill with TB and 1.5 million died from the disease in 2018 alone [1]. The only licensed TB vaccine, bacille Calmette–Guérin (BCG), provides partial protection against severe forms of TB in infants and young children (averting thousands of paediatric deaths annually), but fails to stop transmission of pulmonary tuberculosis in adults [3, 4]. A multidisciplinary framework is needed to guide the research needed for making economic and health impact arguments for tuberculosis vaccine development and uptake <http://bit.ly/2stNDok>
Clinical characteristics, diagnosis, treatment, and prognosis in lung cancer patients under the age of 45.
Authors: Nektaria Makrilia, Alexios S Strimpakos, Ioannis Gkiozos, Kostas N Syrigos
Journal: Journal of Clinical Oncology (2012)

e17508 Background: Lung cancer remains uncommon among young adults but it causes great loss of life expectancy in this age group. The definition of young age varies in the published studies from 40 to 50 years of age. Methods: Our aim was to assess whether patients diagnosed at young ages have unique clinicopathological and prognostic characteristics. We retrospectively reviewed records of patients aged 45 or younger who were treated for primary lung cancer at a large tertiary center between June 2003 and June 2011. Results: 2,651 patients with lung cancer were screened of whom 73 (2.8%) were aged ≤45. The male-to-female ratio was 1.6:1 and the median age at diagnosis was 42. 89% of patients were smokers. Performance status (PS) was 0, 1 and 2 in 61%, 29% and 10% of patients, respectively. The most common histological types were adenocarcinoma (47%), small-cell lung cancer (SCLC) (18%) and squamous cell carcinoma (18%). The median time elapsing between beginning of symptoms and diagnosis was 3 months. Chronic hepatitis B or C was mentioned in the medical history of 5/13 (38%) SCLC patients, whereas it was present in 4/60 NSCLC patients under 45 (p=0.008) and in 16/518 SCLC patients over the age of 45 (p&lt;0.0001). Patients were diagnosed with stages I, II, III and IV in 2 (3%), 11 (18%), 13 (22%) and 34 (57%) of NSCLC cases, respectively, whereas 7 of 13 (54%) SCLC patients were diagnosed with limited disease. The median overall survival was 21 months and multivariate analysis indicated that PS and time until diagnosis were independent prognostic factors. Conclusions: Although more than half of young patients are at stage IV when diagnosed, prognosis does not seem as dismal as previously considered. Larger studies need to be conducted in order to elucidate the possible role of chronic hepatitis in the pathogenesis of SCLC in young patients.
Quality of life and symptom burden in Chinese cancer patients: Results of a multicenter research project.
Authors: Qi Mei, Li-ya Hu, Yuan Chen, Shi Ying Yu, Sheila Payne
Journal: Journal of Clinical Oncology (2013)

e20695 Background: McGill QOL Questionnaire is a well known tool in the evaluation of both psychological and physical states in cancer patients. A number of translations have been made. It is widely used in western developed countries, yet little research has been performed in caner patients in Mainland China who speak Mandarin. Methods: In the first application of the MQOL-Chinese version, which was translated from the MQOL-English version, reliability, content and construct validity testing has been performed among the 126 cancer patients, screened from Tongji Hospital, a medical unit which can deliver comprehensive cancer palliative care. And then 170 patients from 4 different hospitals in China were randomly selected to fill in this scale. Results: First Test-retest reliability of the questionnaire is highly favorable, and all MQOL scores are internally consistent. Using a scientific Stratified Analysis, in the psychological domain, men report less negative emotions than females (question 5\6\8 P=0,002 \0,047\0,016), and patients with head and neck cancer have less negative emotions than those with thoracic cancer (question14 P=0.035).Furthermore, cancer patients less than 20 years old tend to be mentally stronger while people at 40-60 years old seem to have the greatest psychological burden (question6/7 P=0.034/0.017). In the semi-open questions in the second part about the physical domain, poor appetite is reported as the most troublesome problem (M=6.6/10, SD=2.77), while sleep problems rank the least distessing (M=4.2/10,SD=2.15).In the fourth part of the open questions, feeling encouraged is the most frequently mentioned, and physical and economic burden rank the 2nd and 3rd respectively. Conclusions: First of all, the MQOL-Chinese version is a valid instrument for measuring quality of life for cancer patients in Mainland China who speak Mandarin. Moreover, the outcomes above indicated that the psychological and physical domain need to receive more attention, and economic burden is also an urgent problem which needs to be improved among cancer patients especially in China, which is still a developing country with a huge population.
Non-catalytic ubiquitin binding by A20 prevents psoriatic arthritis–like disease and inflammation
Authors: Bahram Razani, Michael I. Whang, Francis S. Kim, Mary C. Nakamura, Xiaofei Sun, Rommel Advincula, Jessie A. Turnbaugh, Mihir Pendse, Priscilia Tanbun, Philip Achacoso, Peter J. Turnbaugh, Barbara A. Malynn, Averil Ma
Journal: Nature Immunology (2020)
FOLLOW-UP OUTCOMES AFTER CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION: DOES SUCCESSFUL REVASCULARIZATION MATTER ?
Authors: Iosif Xenogiannis, Dimitrios Karmpaliotis, Oleg Krestyaninov, Dmitrii Khelimskii, Jaikirshan Khatri, Khaldoon Alaswad, Anthony Doing, Phil Dattilo, Farouc Jaffer, Mitul P. Patel, Ehtisham Mahmud, Wissam Jaber, Habib Samady, Raj Chandwaney, Fotios Gkargkoulas, Ziad Ali, Michael Megaly, Mohamed Omer, Evangelia Vemmou, Ilias Nikolakopoulos, Ross Garberich, Bavana Rangan, Shuaib Abdullah, M Nicholas Burke, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF INCOMPLETE REVASCULARIZATION OF THE LEFT ANTERIOR DESCENDING ARTERY VERSUS OTHER CORONARY ARTERIES AFTER PCI: INSIGHTS FROM THE RIVER-PCI TRIAL
Authors: Toshiki Kuno, Giora Weisz, Philippe Genereux, Bimmer Claessen, Andres Iñiguez, Aleksander Zurakowski, Michael Shechter, Karen Alexander, Stefan K. James, Erik Magnus Ohman, Ovidiu Dressler, Roxana Mehran, Ori Ben-Yehuda, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC VALUE OF REGIONAL AND GLOBAL WALL MOTION SCORE INDEX BY ECHOCARDIOGRAPHY IN THE GENERAL POPULATION
Authors: Caroline Espersen, Daniel Modin, Elke Platz, Gorm Jensen, Peter Schnohr, Eva Prescott, Gunnar Gislason, Rasmus Moegelvang, Tor Biering-Soerensen
Journal: Journal of the American College of Cardiology (2020)